Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. 

Biotechnology

Bolt Biotherapeutics

Randall Schatzman

Murray Nguyen

Christine Gustin

Samara Violet

Jason Ptacek

Jenny Yuan

Seth M.

Lindsey Gourley

Anthony Wong

Kristi Balacy

Arthur Lee

Husein Hadeiba

Coya Tapia

Dawn Colburn

Willie Quinn

Lynn Ferguson Lewis

Pam Howland

Nathan Ihle

Grant Yonehiro

Michael N. Alonso

Wesley Burwell

Lu Xu

Sarah Nemec

The Leadership Team at Bolt Biotherapeutics is responsible for setting the strategic direction and overseeing the overall operations of the company. Comprising experts in various fields such as business development, immunology, and finance, this team collaborates to drive innovation in the development of Boltbody™ ISAC therapeutics, ensuring that the company's vision aligns with its clinical and commercial goals while fostering a culture of excellence and collaboration.

Leadership Team

Clinical Development and Research

Laboratory Operations and Quality Control

Leadership Team

About

Team members

Other teams at Bolt Biotherapeutics

Clinical Development and Research

Laboratory Operations and Quality Control